Osavampator not checked

Neurocrine Biosciences · NBI-1065845 · TAK-653

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
8 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Major Depressive Disorder (5 trials)
Main trialPhase 3
“The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.”In the company’s words, NCT06963021 on ClinicalTrials.gov
Other names
NBI-1065845 · TAK-653

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2027 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2027 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2027 Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2028 A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting May 2029 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 2Completed 10 Jan 2024 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Phase 1Completed 11 Sep 2017 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
Phase 1Completed 15 May 2019 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Osavampator

Following is part of Solo: you see every change to Osavampator the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in